244151-94-8

Basic information

• Product Name: 1H-Pyrrolo[1,2-a]benzimidazol-3-amine,2,3-dihydro-7-methyl-,(3R)-(9CI)
• Synonyms: 1H-Pyrrolo[1,2-a]benzimidazol-3-amine,2,3-dihydro-7-methyl-,(3R)-(9CI)
• CAS NO: 244151-94-8
• Molecular Formula: C11H13N3
• Molecular Weight: 187.24102
• Product Categories: BENZIMIDAZOLE
• Mol File: 244151-94-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Pyrrolo[1,2-a]benzimidazol-3-amine,2,3-dihydro-7-methyl-,(3R)-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[1,2-a]benzimidazol-3-amine,2,3-dihydro-7-methyl-,(3R)-(9CI)(244151-94-8)
• EPA Substance Registry System: 1H-Pyrrolo[1,2-a]benzimidazol-3-amine,2,3-dihydro-7-methyl-,(3R)-(9CI)(244151-94-8)

Safety Data

• Hazardous Substances Data: 244151-94-8(Hazardous Substances Data)

Upstream product

• 244151-91-5 N-(7-methyl-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-3-yl)-acetamide 
• 244151-81-3 3-amino-2,3-dihydro-7-methyl-1H-pyrrolo[1,2-a]benzimidazole 

Downstream Products

• 244152-36-1 (6-bromo-7-methyl-5-nitro-2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-3-yl)-carbamic acid phenyl ester 

Relevant articles and documents

Treatment of neoplasms with yujungamycins

Yungamycin A has been demonstrated to have unexpected in vivo anticancer activity. New compounds Yungamycin B and C are also disclosed, and have been demonstrated to be specific for DT-diaphorase, as well as to have in vivo anticancer activity.

Design of highly active analogues of the pyrrolo[1,2-a]benzimidazole antitumor agents

The pyrrolo[1,2-a]benzimidazole (PBI) reductive alkylating agents have been investigated in this laboratory since their discovery in the late 1980s. Of all the structural modifications of the PBIs investigated so far, the variation of the 3-substituent has the greatest influence on cytotoxicity, toxicity, and in vivo antitumor activity. In the present study, we prepared both the R and S enantiomers of nitrogen-containing 3-substituents possessing hydrogen-bonding capability as well as varying basicity. The rationale was to take advantage of stereoselective DT-diaphorase reductive activation as well as hydrogen bonding in the DNA major groove. As a result of these studies, analogues were discovered possessing among the highest hollow fiber tumor assay scores observed in hundreds of natural and synthetic antitumor agents. Our findings indicate that a relatively basic 3-substituent is required for outstanding PBI cytotoxicity but that the importance of using pure enantiomers is still open to study.